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Hypoxia and overexpression
of EGFR are common char-
acteristics of head-and-neck
cancers. Colocalization of
both factors might define
a critical subpopulation
responsible for local recur-
rence, metastasis formation,
or treatment resistance. In
the present study colocaliza-
tion with hypoxia was found
in a series of head-and-neck
squamous cell carcinomas.
The amount of colocalization
was associated with
outcome, indicating
a survival advantage for
hypoxic cells expressing
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Open access undPurpose: Overexpression of epidermal growth factor receptor (EGFR) and tumor hypoxia have
been shown to correlate with worse outcome in several types of cancer including head-and-neck
squamous cell carcinoma. Little is known about the combination and possible interactions
between the two phenomena.
Methods and Materials: In this study, 45 cases of histologically confirmed squamous cell carci-
nomas of the head and neck were analyzed. All patients received intravenous infusions of the
exogenous hypoxia marker pimonidazole prior to biopsy. Presence of EGFR, pimonidazole
binding, and colocalization between EGFR and tumor hypoxia were examined using immuno-
histochemistry.
Results: Of all biopsies examined, respectively, 91% and 60% demonstrated EGFR- and
pimonidazole-positive areas. A weak but significant association was found between the hypoxic
fractions of pimonidazole (HFpimo) and EGFR fractions (F-EGFR) and between F-EGFR and
relative vascular area. Various degrees of colocalization between hypoxia and EGFR were
found, increasing with distance from the vasculature. A high fraction of EGFR was correlated
with better disease-free and metastasis-free survival, whereas a high degree of colocalization
correlated with poor outcome.
Conclusions: Colocalization of hypoxia and EGFR was demonstrated in head-and-neck squa-
mous cell carcinomas, predominantly at longer distances from vessels. A large amount of colo-
calization was associated with poor outcome, which points to a survival advantage of hypoxic
cells that are also able to express EGFR. This subpopulation of tumor cells might be indicative
of tumor aggressiveness and be partly responsible for treatment resistance.
 2012 Elsevier Inc.
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Hoogsteen et al. International Journal of Radiation Oncology  Biology  Physics808Introduction Immunohistochemical stainingSquamous cell carcinoma of the head and neck (HNSCC) is
a significant cause of morbidity and mortality, with approximately
600,000 new cases worldwide (1). Much effort has been put into
developing novel agents and optimizing treatment focusing on
organ preservation and improvement of survival (2). Information
on the molecular status of head-and-neck cancer and the ability to
develop specific molecular profiles would permit optimization and
selection of the appropriate therapy for the individual patient with
less toxicity.
One key factor that plays a central role in HNSCC is the
epidermal growth factor receptor (EGFR). EGFR belongs to the
ErbB/HER family of tyrosine kinases. It is a membrane-associated
receptor, and ligand binding induces activation of the intrinsic
kinase domain, leading to stimulation of various downstream
signaling pathways (3). Triggering this network mediates
a multitude of cellular responses including cell growth, prolifer-
ation, apoptosis, migration, and angiogenesis (4). Overexpression
of EGFR was found in most epithelial malignancies including
HNSCC, and it has been shown to correlate with worse outcome in
HNSCC (3, 5).
Another important aspect of solid tumors is tumor hypoxia.
It has a strong effect on tumor cell biology, providing an
overall selective advantage for malignant growth. It promotes
genetic and proteomic changes leading to increased metas-
tasis, angiogenesis, and selection of cells with diminished
apoptotic potential (6). Tumor hypoxia has been associated
with worse outcome in various types of cancer, including
HNSCC (7).
Inhibitors of EGFR are among the most promising molec-
ular targeting agents for combination with radiotherapy (2),
and the same accounts for therapies directed at counteracting
tumor hypoxia (8). Despite the importance of EGFR and
tumor hypoxia in cancer development, both strategies have had
limited success thus far. Detailed understanding of the
underlying mechanisms is therefore necessary. Colocalization
of both factors might define a critical subpopulation respon-
sible for local recurrence, metastasis formation, or treatment
resistance. The purpose of the present study was to investigate




Between 1998 and 2002, 53 patients with HNSCC were included
in our hypoxia marker study at the Radboud University Nijmegen
Medical Centre. Patients with primary stage II-IV squamous cell
carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx
were enrolled. Approval from the local ethics committee was
obtained.
Approximately 2 h before patients underwent biopsies, they
received a 20-min intravenous infusion of the hypoxia marker
pimonidazole hydrochloride (500 mg/m2; Hypoxyprobe-1; NPI,
Inc., Belmont, MA). Biopsy samples were taken for routine
diagnostic purposes, and additional biopsy samples were taken for
hypoxia marker analysis. The latter samples were snap frozen in
liquid nitrogen until immunohistochemical processing.From frozen biopsy material, sections of 5 mm were cut and
mounted on poly-L-lysine coated slides, followed by fixation in
acetone at 4C and rehydration in phosphate-buffered saline (PBS;
Klinipath, Duiven, The Netherlands). Sections were incubated in
primary antibody diluent (PAD; GeneTex Inc., San Antonio, TX)
for 5 min at room temperature. Sections were incubated overnight
at 4C with goat-anti-EGFR antibody (Santa Cruz Biotechnology,
Santa Cruz, CA) diluted 1:50 in PAD, followed by incubation with
donkey-anti-goat Cy3 antibody (Jackson Immunoresearch Labo-
ratories, West Grove, PA) at 1:600 dilution in PBS. For detection
of pimonidazole, sections were incubated with rabbit-anti-pimo
antibody (from J.A. Raleigh, Department of Radiation Oncology
and Toxicology, University of North Carolina, Chapel Hill) diluted
1:1,000 in PAD, followed by incubation with donkey-anti-rabbit
Alexa488 (Molecular Probes, Leiden, The Netherlands) antibody
diluted 1:600 in PBS. Sections were rinsed with PBS and stained
for vessels by incubation with mouse antibody PAL-E (Euro
Diagnostica, Arnhem, The Netherlands) diluted 1:10 in PAD,
followed by incubation with chicken-anti-mouse Alexa647 anti-
body (Molecular Probes) 1:100 in PBS. Sections were mounted in
Fluorostab (ProGen Biotechnik GmbH, Heidelberg, Germany).
Image acquisition
Tissue sections were scanned using a digital image processing
system consisting of a high-resolution 12-byte charge-coupled
device camera (Micromax; Roper Scientific, Trenton, NJ) on
a fluorescence microscope (Axioskop, Zeiss, Go¨ttingen, Germany)
and a computer-controlled motorized stepping stage. Image pro-
cessing was done using IPLab software (Scanalytics, Inc., Fairfax,
VA) on a Macintosh (Cupertino, CA) computer. Each tissue
section was scanned for pimonidazole, EGFR, and vessel signals
at 200 magnification. Resulting composite gray-scale images
were converted to binary images for further analysis. Thresholds
for segmentation of the fluorescent signals were interactively set at
intensities where the steepest gradient occurred between back-
ground and foreground intensity levels. Different intensities of
EGFR expression were observed. To investigate a potential
influence, the intensity of EGFR staining was also interpreted
semiquantitatively by visual inspection at 100 magnification.
Biopsy results were divided into three groups according to weak,
moderate, and strong intensity levels. To facilitate further analysis,
in these particular groups, thresholds for segmentation were set at
the same levels. The corresponding composite binary images were
superimposed onto one pseudo-colored image for visual
evaluation.
Analysis
For examination of immunohistochemical staining, one complete
section per tumor was investigated. Tumor area delineation was
guided by hematoxylin-eosin staining. This delineated area was
subsequently used as a mask in further analysis from which
nontumor tissue, necrotic areas, and artifacts were excluded. The
fractions based on pimonidazole (hypoxic fraction; HFpimo) and
EGFR staining (F-EGFR) were defined as the tumor area positive
for pimonidazole or EGFR, relative to the total tumor area.
Vascular density was calculated as the number of vascular
Table 1 Patient and tumor characteristics






























Surgery and adjuvant radiotherapy 7
No treatment 3y
* All patients were stage M0.
y All patients died before treatment could start.
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(RVA) was defined as the PAL-E positive area divided by the total
tumor area (pixels). To determine colocalization of EGFR and
pimonidazole, the fraction of the total EGFR-stained area that was
also positive for pimonidazole was measured. The area positive
for both pimonidazole and EGFR was divided by the total EGFR-
positive area (F-EGFR[pimo]). To determine the distribution of
hypoxia, EGFR, and colocalization of both parameters in relation
to the vasculature, zones were chosen arbitrarily at increasing
distances from the surface of the nearest vessel (<50 mm, 50e100
mm, 101e150 mm, 151e200 mm, 201e250 mm, and >250 mm),
and for each parameter, a zonal fraction was calculated.
Statistical methods
Statistical analyses were carried out with a Macintosh computer
using Prism version 4.0 software (Hearne Scientific Software,
Dublin, Ireland). Correlations between the different parameters
were assessed using the Pearson chi-squared test. To determine
correlations and differences between these parameters and cate-
gorical tumor characteristics the Spearman correlation coefficient
and one-way analysis of variance tests were applied. Survival rates
were calculated from the date of histological diagnosis using the
Kaplan-Meier method, and the logerank test was used to test for




This study included 53 patients. Pimonidazole was given to all
patients before biopsies were performed, and none of the patients
had adverse reactions. Three patients were excluded from the final
analysis because the biopsy result was of poor quality, attributable
to mechanical damage during staining or biopsy. It was observed
that in five biopsies, EGFR was found in the nuclei of cells only.
Because of the unclear role of nuclear EGFR in HNSCC, these
biopsies were considered a separate group and were not included
in further analysis of the membranous EGFR, but they were
analyzed separately. Thus, 45 histologically confirmed cases of
HNSCC were analyzed. Table 1 shows patient and tumor
characteristics.
Pimonidazole, EGFR, and vessel staining
All markers gave strong and bright fluorescent signals with little
background, except in areas of necrosis and occasionally in
stromal components of the tumor. Pimonidazole binding was
observed in the cytoplasm, whereas EGFR staining was predom-
inantly confined to the cell membrane. Besides membrane stain-
ing, in approximately 25% of biopsies, EGFR was also observed
in the nucleus of the cell. The membranous expression pattern,
however, was strongly dominant. Nuclear EGFR could be seen in
both well-oxygenated and hypoxic regions. In five biopsies, EGFR
was confined to nuclei. Interestingly, in some of these biopsies, no
or very little pimonidazole binding could be detected, indicating
that these tumors are well oxygenated.
Different intensities of EGFR staining could be observed, and
biopsy sample intensities were therefore divided into three groups,namely, weak (n Z 27), moderate (n Z 13), and strong (n Z 5).
Figure 1 shows examples of EGFR expression with different
intensity levels and hypoxia represented by pimonidazole binding.
Pimonidazole binding usually increased farther away from the
blood vessels and could frequently be observed near necrosis.
EGFR was more diffuse in the tumor, with the highest expression
levels at intermediate distances (50e100 mm and 101e150 mm)
from the blood vessels. Mean, median, and range values for all
parameters are shown in Table 2.
Of all biopsy results, 91% and 60% demonstrated EGFR and
pimonidazole positive areas (1% of the tumor area), respec-
tively. A weak but significant correlation between F-EGFR
and HFpimo could be found (r Z 0.35, p Z 0.018) (Fig 2A).
Also, a weak association was found between F-EGFR and RVA
(rZ 0.38, pZ 0.005) (Fig 2B). No other significant correlations
could be demonstrated between parameters. Between the micro-
environmental parameters tested and known tumor characteristics
such as T stage, N stage, tumor site and differentiation grade, no
correlations were observed.
Colocalization between pimonidazole and EGFR
Among biopsy samples, various degrees of colocalization between
pimonidazole and EGFR could be found, with a maximum of
Fig. 1. Merged fluorescent colored images of biopsy samples from two oropharyngeal carcinomas, both showing tumor hypoxia
(pimonidazole binding, green), EGFR expression (red), and vessels (white). (A) High EGFR intensity and (B) low EGFR intensity. Original
single channel images (gray value) for each parameter are also shown.
Hoogsteen et al. International Journal of Radiation Oncology  Biology  Physics81024%. In a single biopsy sample, areas of colocalization could be
found but also areas of mismatch. In some samples with pimo-
nidazole binding and EGFR expression, no colocalization could
be detected, and EGFR was then present mainly in better
oxygenated areas. When colocalization was observed, it usually
increased with distance from the blood vessels (with largest
amount at 250 mm). Figure 3 shows an example of EGFR
expression in a hypoxic area.Survival analysis
For survival analysis, the patient group was divided by the
median values for HFpimo, F-EGFR, and F-EGFR[pimo](Fig. 4). For HFpimo, no significant differences between
the subgroups were observed for the various endpoints. For
F-EGFR, no difference between the subgroups was found in
locoregional control rate; however, a weak significant difference
(p Z 0.05) was found in metastasis-free survival, and a 5-year
disease-free survival rate of 60% vs. 31%, respectively, for
patients with a high F-EGFR and patients with a low F-EGFR
(p Z 0.02) could be demonstrated. This was also repeated for
the different treatment groups, and it was found consistently
that patients with a high F-EGFR treated with accelerated
radiotherapy alone had better survival (data not shown). The 5
patients from whom biopsy samples demonstrated only nuclear
EGFR had a comparable 5-year locoregional control rate (75%)
and a slightly better 5-year disease-free survival rate (41%) than
Table 2 Values for hypoxic and vascular parameters in 45 biopsies of head and neck squamous cell carcinomas
Parameter HFpimo (%) F-EGFR (%) VD (N/mm2) RVA (%) F-EGFR[pimo] (%)
Mean 3.4 16.1 341.6 1.0 4.6
Median 1.2 9.6 292.6 0.7 2.7
Range 0e14.1 0e61.5 153.6e853.2 0.2e3.4 0e24.3
SD 3.9 15.8 158.5 0.7 5.6
Abbreviations: F-EGFRZ EGFR fraction; F-EGFR[pimo]Z area positive for both pimonidazole and EGFR divided by the total EGFR-positive area;
HFpimo Z pimonidazole hypoxic fraction; RVA Z relative vascular area; SD Z standard deviation; VD Z vascular density.
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found.
For F-EGFR[pimo], a significant difference was found between
the locoregional control rates of the groups (pZ 0.03). Five-year
locoregional control was 77% for patients with low F-EGFR[pimo]
vs. 38% for patients with high values. A high F-EGFR[pimo]
showed a trend toward worse disease-free survival (pZ 0.06). No
significant difference was observed in metastasis-free survival.
Chi-square test results did not indicate any significant differences
in distribution of T stage, tumor site, and treatment modality
between the two subgroups. Stratification into three groups for
staining intensity of EGFR yielded no significant differences for
locoregional control or metastasis-free and disease-free survival
rates.
Discussion
The principle aim of the present study was to explore the presence
of EGFR under hypoxic conditions. With the triple-staining
method used in this study, colocalization of hypoxia and EGFR
was found with increasing distance from blood vessels. This
suggests that a subpopulation of tumor cells exists under hypoxic
conditions expressing EGFR that might be relevant for clinical
outcome. This hypothesis is supported by the results shown here,
where the amount of colocalization between hypoxia and EGFR
was significantly associated with worse locoregional control.
Furthermore, a trend toward an association with disease-freeFig. 2. Scatterplots comparing F-EGFR with HFpimo (A) and F-EG
patients. Linear best fit is shown.survival was observed. Although the sample size was small and
interpretation of data should be done carefully, it points to
a survival advantage of hypoxic cells that are also able to express
EGFR. To our knowledge, this is the first clinical study exploring
the relationship between EGFR and hypoxia in HNSCC and
demonstrating such a relationship. The potential influence on
outcome is currently being investigated further in a large
randomized trial using oxygenation modification in laryngeal
cancer (8, 9).
Intensive research has recently focused on EGFR as the
potential target for cancer therapy. In the present study, 90% of the
biopsy samples examined demonstrated weak to strong membra-
nous expression of EGFR. This finding is in agreement with those
of earlier studies in which at least 80% of all HNSCC EGFR was
found to be overexpressed compared to the level in normal
mucosa of patients without cancer (5, 10). In 25% of the samples,
incidental nuclear EGFR staining was observed, and five samples
demonstrated exclusively nuclear EGFR staining. The clinical
significance of this phenomenon is unclear, and we are currently
investigating this in a larger cohort of patients.
Another clinically relevant obstacle is tumor hypoxia. Hypoxia
is considered one of the causes of radioresistance. Clinical studies
in HNSCC (7) and uterine cervix (6) have demonstrated a signif-
icant correlation between hypoxia and poor response to radio-
therapy. In this study, a positive, albeit weak, relationship between
hypoxia and fraction EGFR was found. In studies from the 1980s,
it was found that a reduction in oxygen probably inhibits EGFR
down-regulation (11). Furthermore, exposure of different humanFR with RVA (B) in 45 head-and-neck squamous cell carcinoma
Fig. 3. Merged fluorescent image of a biopsy sample from a hypopharyngeal carcinoma SccNij49, showing EGFR expression (red) under
hypoxia (green) (arrows). Colocalization was found at increasing distance from the blood vessels (white).
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aerobic cells (12). From these studies, it can be concluded that
most observations underscore a role for hypoxia in inducing
expression of EGFR, which is in agreement with the results ob-
tained here. Improved understanding of this process will provide
a mechanistic basis for optimization of treatment strategies.
EGFR, in turn, also increases the response to hypoxia by
inducing proteins that promote cellular survival. From previous
studies in tumor cell lines, it is known that EGFR is involved in
the response to hypoxia through one of its major downstream
targets, the PI3-K/Akt pathway (13). Blockage of this pathway
results in a dramatic reduction of hypoxic tumor cell viability and
contributes to an improvement of tumor control (14). To some
extent, several hypoxia-related markers such as hypoxia-inducible
transcription factor 1 (HIF-1) and carbonic anhydrase IX (CA-IX)
are under the control of the EGFR/P13-K/Akt pathway (4). Inhi-
bition of EGFR resulted in not only downregulation of HIF-1a and
CA-IX but also a decrease in hypoxia as measured with the
nitroimidazole hypoxia-marker EF5 (15). This was explained by
vascular normalization and improved blood flow. In the present
study, a positive relationship between EGFR expression and RVA
has been found. Although this seems to be in contradiction to the
positive relationship between the fraction EGFR and the hypoxic
fraction, the RVA does not take into account whether blood vessels
are perfused or not, because of the absence of a good perfusion
marker for human use, and the RVA only reflects the areacontaining vascular structures. Activation of vascular endothelial
growth factor (VEGF) through EGFR leads to the induction of
neoangiogenesis, which is often disorganized and functionally
impaired. These defects in turn contribute to tumor hypoxia.
Blockade of VEGF by EGFR inhibition was shown to decrease
angiogenesis, leading to normalization of vasculature, an increase
in blood perfusion, and a reduction in hypoxia (16). These results
implicate an important role for EGFR in hypoxic tumor cells by
promoting cellular survival and providing a powerful adaptive
advantage during carcinogenesis.
Surprisingly, it was found that for patients with a high fraction
of EGFR, time to disease recurrence was significantly longer. The
presence of EGFR has been related to poor locoregional control in
head-and-neck carcinomas treated with conventional radiotherapy
by Ang et al. (5). Only patients who were randomized to the
conventional radiotherapy arm of Radiation Therapy Oncology
Group (RTOG) Phase III trial were included. Studies by Eriksen
et al. (10) and Bentzen et al. (17) demonstrated that tumors with
high EGFR expression levels benefit most from, respectively,
accelerated radiotherapy and continuous hyperfractionated accel-
erated radiotherapy with an increase in locoregional control and
disease-specific survival, while there was no benefit of accelera-
tion for tumors with low EGFR. Increased activity of EGFR
contributes to enhanced cellular proliferation and additionally an
increase in their capacity for DNA damage repair, which may
confer resistance to radiotherapy (18). This can be counteracted by
Fig. 4. Kaplan-Meier estimates for locoregional control and metastasis- and disease-free survival stratified by the median of F-EGFR (A)
and F-EGFR[pimo] (B). Survival functions were compared using the logerank test.
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explaining the preferential response to this approach in tumors
with high EGFR expression (17). In this relatively small group of
45 patients, 25 patients underwent accelerated radiotherapy, and
the same results were found for these patients, with a fraction of
EGFR that was as high as that for the total group of patients. It is
therefore possible that this may account for the positive correla-
tion found between a high fraction EGFR and disease-free
survival. Some remarks however, must be made regarding the
present study. The population studied was rather small, and
patients in this group underwent various treatments from surgery,
conventional or accelerated radiotherapy with or without chemo-
therapy. Stratification by treatment modality left few cases per
group for reliable statistical analyses.Conclusions
In conclusion, it was possible to quantify colocalization of
hypoxia assessed by the pimonidazole-binding assay and EGFR,
which was further associated with poor locoregional control. This
suggests not only a direct link between EGFR and hypoxia but
also the fact that EGFR expression under hypoxic conditions may
act as a survival factor for hypoxic tumor cells. This subpopulation
of tumor cells might therefore be responsible for enhanced treat-
ment resistance and ultimately poor outcome. Currently, all
microenvironmental parameters are under investigation in a large
series of laryngeal carcinomas included in our Phase III ARCON
trial combining Accelerated Radiotherapy with CarbOgen
breathing and Nicotinamide (9).References
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